MK-4250
Total Payments
$562,191
Transactions
26
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $29,073 | 5 | 0 |
| 2019 | $41,653 | 4 | 0 |
| 2018 | $491,465 | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $562,191 | 26 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 6-Week, Multiple-Dose Clinical Study to Evaluate the Safety, Tolerabilityand Pharmacokinetics of MK-4250 in Healthy Participants | Merck Sharp & Dohme Corporation | $303,395 | 0 |
| An Open Label Clinical Trial to Evaluate the Pharmacokinetics and Relative Bioavailability of Five Formulations of MK-4250 in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $255,362 | 0 |
| STUDY NAME# A 6-Week, Multiple-Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-4250 in Healthy Participants | Merck Sharp & Dohme Corporation | $3,434 | 0 |
Top Doctors Receiving Payments for MK-4250
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $562,191 | 26 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $562,191
Product Information
- Type Drug
- Total Payments $562,191
- Total Doctors 0
- Transactions 26
About MK-4250
MK-4250 is a drug associated with $562,191 in payments to 0 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $29,073 was paid across 5 transactions to 0 doctors.
The most common payment nature for MK-4250 is "Unspecified" ($562,191, 100.0% of total).
MK-4250 is associated with 3 research studies, including "A 6-Week, Multiple-Dose Clinical Study to Evaluate the Safety, Tolerabilityand Pharmacokinetics of MK-4250 in Healthy Participants" ($303,395).